Take MAP & the sky is the limit!

    ABOUT MAP™

    MAP Master Amino Acid Pattern® is a safe and nutritionally effective substitute for dietary proteins. The results of comparative, double-blind, triple and quintuple crossover Net Nitrogen Utilization® (NNU®) clinical studies1-10 have shown that the use of MAP™ can provide a body's 99% Net Nitrogen Utilization® (NNU®), for body protein synthesis (BPS). Namely, the highest NNU® in comparison to any dietary protein or protein supplement. This fact confirms that the use of MAP Master Amino Acid Pattern® can substitute dietary proteins in a safer and nutritionally more effective way.  After oral ingestion, MAP™ is rapidly utilized. MAP™ does not require the aid of peptidases and therefore is absorbed within 23 minutes through the first 100 cm of functional small intestine. MAP™ does not provide any fecal residue. MAP™ is amphoteric. MAP™ is supplied in 120 tablets of 1,000 mg for oral administration. Each tablet of MAP™ contains only the active ingredient MAP™. MAP™ contains no inactive ingredients.

    COMPOSITION

    MAP Master Amino Acid Pattern® provides an unparalleled amino acids formula that contains a unique pattern of essential amino acids, described in U.S. Patent No. 5,132,113, such as L-Leucine, L-Valine, L-Isoleucine, L-Lysine HCl, L-Phenylalanine, L-Threonine, L-Methionine, L-Tryptophan,  in a highly purified, free, crystalline form. Each tablet of MAP™ contains only the active ingredient MAP™. MAP™ contains no inactive ingredients.

    CLINICAL STUDIES

    The results of comparative, double-blind, triple and quintuple crossover Net Nitrogen Utilization® (NNU®) clinical studies1-10 have shown that the subjects, while taking MAP™, as a dietary proteins substitute, achieved a body's 99% NNU®. This means that 99% of MAP™'s constituent amino acids followed the anabolic pathway, thus acting as precursor of body's protein synthesis (BPS), namely as “building blocks”. By comparison, dietary proteins only provide an average between 16 to 32% NNU®. This fact evidences that MAP™ is more nutritious than dietary proteins. This has been confirmed by the fact that during the study, each subject body's nitrogen balance was maintained in equilibrium by taking MAP™, as a sole and total substitute of dietary proteins, in a dosage of only 400 mg/kg/day, which provided less than 2 kcal/day (1g MAP™= 0.04 Kcal). The study results have also shown that 1% of MAP™'s constituent amino acids followed the catabolic pathway, thus releasing only 1% of nitrogen catabolites (NC) and energy. By comparison dietary proteins release between 68% to 84% nitrogen catabolites and energy. This fact evidences that the use of MAP™ is safer than that of dietary proteins, and that provides the lowest amount of energy in comparison to any dietary protein.

    Figure 1. Dietary Protein Metabolism

    To illustrate: when a dietary protein is digested, it releases its constituent amino acids into the small intestine where they are absorbed. Then, those amino acids can follow either the anabolic pathway (build-up) or the catabolic (breakdown) pathway.


    Figure II. The Protein Metabolism Anabolic Pathway

    When dietary amino acids follow the anabolic pathway, they act as precursors for the body’s protein synthesis, thus becoming the body’s constituent proteins. Throughout the anabolic pathway, amino acids  do not release any nitrogen catabolites or energy.


    Figure III. The Protein Metabolism Catabolic Pathway

    On the other hand, when dietary amino acids follow the catabolic pathway, they act only as a source of energy and not as precursors of Body’s Proteins Synthesis (BPS). Throughout the catabolic pathway, amino acids do release nitrogen catabolites ( toxic metabolic waste) and energy.

    INDICATIONS AND USAGE

    The use of MAP™ is recommended as a safe and nutritionally effective substitute for dietary proteins.

    DOSAGE AND ADMINISTRATION

    MAP™ should be orally administered, preferably with food. MAP™ in a dosage of 400mg/kg*/day (*ideal weight) has been shown to be adequate as a sole and total substitute of dietary proteins to maintain the body’s nitrogen balance in equilibrium. To calculate the MAP™ dosage necessary to substitute dietary proteins, apply the following:


    MAP™ dosage = (Dietary Protein x 0.4) g


    For instance, to calculate the dosage of MAP™ necessary to substitute 10 g of high biological value dietary proteins, proceed as follows:

    1. MAP™ dosage = (Dietary Proteins x 0.4) g
    2. MAP™ dosage = (10 x 0.4) g
    3. MAP™ dosage = 4 g

    Therefore, 4 g (4 tablets) of MAP™ provide a body’s protein synthesis (BPS) equivalent to that provided by at least 10 g of dietary protein with the highest biological value.

    If administering more than 10 tablets per day, increase dosage gradually. (Not more than 10 tablets should be administered within a two hour period.)

    OVERDOSAGE

    No adverse reactions have been reported.

    ADVERSE REACTIONS 

    No adverse reactions have been reported.

    INFORMATION

    MAP™ is available in bottles of 120 tablets of 1,000 mg, for oral administration. Each tablet of MAP™ (1g) contains only the active ingredient MAP™. MAP™ contains no inactive ingredients.


    Additional professional information on MAP™ is available through the International Nutrition Research Center, Inc. at www.masteraminoacidpattern.com



    SCIENTIFIC REFERENCES RELATED TO MAP MASTER AMINO ACID PATTERN®


    1. Lucà-Moretti M. Comparative study of subjects’ Net Nitrogen Utilization (NNU) while receiving SON, a nutritional amino acid formula, or high biological value egg protein, or egg protein amino acid formula. JIMHA; 1:33-42, 1992.
    2. Lucà-Moretti M. Comparative study of subjects’ Net Nitrogen Utilization (NNU) while receiving SON, or egg protein or its protein amino acid formula. Advances in Therapy; 5:280-89, 1992.
    3. Lucà-Moretti M. Comparative study of subjects’ Net Nitrogen Utilization (NNU) while receiving bovine milk or soybean flour with or without SON nutrification. JIMHA; 1:43-54, 1992.
    4. Lucà-Moretti M. Comparative study of subjects’ Net Nitrogen Utilization (NNU) while receiving bovine milk or soybean flour with or without SON nutrification. Advances in Therapy; 5:290-301, 1992.
    5. Lucà-Moretti M., Grandi, A. The Malnutrition Treatment and Prevention Project. JIMHA; 2:20-26, 1993.
    6. Lucà-Moretti M., Grandi, A. Comparative Study of Subjects’ Weight Loss while receiving Very Low Calorie Diets consisting of SON, SON-Nutrified Dried Bovine Skim Milk, or Dried Bovine Skim milk provided in the required amounts to achieve Zero Nitrogen Balance. JIMHA; 2:39-48, 1993.
    7. Tamburlin N. L’importanza innovativa nell’uso del MAP per il controllo biologico del peso. La Medicina Biologica; 1:4-10, 1997.
    8. Lucà-Moretti M. Ensayo Comparativo sobre el MAP: el perfil ideal de aminoácidos esenciales para la nutrición humana, International Journal for Biomedical Research and Therapy; 4:9-14, 1997.
    9. Lucà-Moretti M. A Comparative, Double-blind, Triple Crossover Net Nitrogen Utilization Study Confirms the Discovery of the Master Amino Acid Pattern. Annals of the Royal National Academy of Medicine of Spain, Madrid; Vol. CXV: 397-416, 1998.
    10. Lucà-Moretti M. A Comparative, Double-blind, Triple Crossover Net Nitrogen Utilization Study Confirms the Discovery of the Master Amino Acid Pattern. Annals of the Royal Academy of Medicine of Zaragoza. Zaragoza; LXXII, 1998.
    11. Lucà-Moretti M. The International Nutrition Research Center Overweight Management Program. The Library of Congress, USA 1999.
    12. Fidone B. Rettocolite ulcerosa idiopatica: possibilita con MAP (SON Formula). La Medicina Biologica; 3:8-11, 1999.
    13. Sanseverino E. R. Vantaggi dell’utilizzo del MAP in eta’geriatrica. La Medicina Biologica; 3:17-19, 1999.
    14. Lucà-Moretti M. Programma di trattamento e prevenzione della malnutrizione. La Medicina Biologica; 3:35-38, 1999.
    15. Costanzo S. Nuova opportunita nella nutrizione delle popolazioni in situazioni di emergenza. La Medicina Biologica; 3:39-42, 1999.
    16. Mariani E., Vender G., Arrigotti E., Ferrario M., Rovelli E. Variazione di alcuni parametri antropometrici e fisiologici in una marciatrice cinquantenne prima e dopo l’attraversamento in solitaria del deserto cinese. La Medicina Biologica; 3:20-25, 1999.
    17. Tamburlin N. Trattamento ambulatoriale di pazienti con insufficienza renale cronica. La Medicina Biologica; 3:12-16, 1999.
    18. Muratori G. Sovrappeso e patologia articolare: SON Formula come terapia dimagrante ed antalgica un’ipotesi di lavoro. La Medicina Biologica; 17-20, 1999.
    19. Montilla C. Studio comparativo con e senza somministrazione di SON FORMULA® in soggetti affetti da anemia sideropenica sotto trattamento convenzionale. La Medicina Biologica; 3:2-7, 1999.
    20. Riccobene F. Impiego della neuralterapia sec. Huneke in casi di ritensione idrosalina non responsivi alla terapia diuretica in corso di dieta dimagrante con SON Formula. La Medicina Biologica; 3:48-52, 1999.
    21. Hermann G.F. Le intolleranze alimentari. La Medicina Biologica; 3:3-7, 2000.
    22. Corgna M. Pnei e patologie psiconutrizionali in omotossicologia. Il trattamento delle sindromi bulimiche. La Medicina Biologica; 3:8-16, 2000.
    23. Tamburlin N. Il SON Formula come opportunita nella gestione delle intolleranzealimentari. La Medicina Biologica; 3:24-29, 2000.
    24. Di Tullio G. Biotipologia del comportamento alimentare e utilizzo del SON Formula. La Medicina Biologica; 3:34-37, 2000.
    25. Ivaldi G.P. Esperienza nutrizionale in pazienti con insufficienza respiratoria. La Medicina Biologica; 3:49-54, 2000.
    26. Bufalini L. Nutrizione biologica integrata con SON Formula in pazienti affetti da sclerosi multipla. La Medicina Biologica; 3:55-61, 2000.
    27. D’Andrea G. Terapia delle obesitá: Studio comparativo di 10 casi clinici trattati con MAP (Son Formula™) e terapia omotossicologica versus Orlistat (Xenical 120mg Roche). La Medicina Biologica; 3:5-9, 2001.
    28. Di Tullio G. La Malattia asmatica: il ruolo della nutrizione biologica. La Medicina Biologica; 3:15-19, 2001.
    29. Del Prete M. Le malattie infiammatorie intestinali: importanza diagnostica e terapeutica del MAP. La Medicina Biologica; 3:20-26, 2001.
    30. Mariani M.M. Utilizzo del MAP (Master Amino acid Pattern) nel Programma “Quattro D” nell’insufficienza venosa cronica. La Medicina Biologica; 3:33-40, 2001.
    31. Falcone S., Cornoldi A., Brandetti F., Pili M., Badiali M., Spera G., Lubrano C. Integrazione con SON Formula in pazienti grandi obesi operati di by-pass biliointestinale presso il Policlinico Umberto I di Roma. La Medicina Biologica; 3:46-52, 2001.
    32. Fidone B. Nutrizione biologica integrata con SON Formula in pazienti affetti da insufficienza cardiaca. La Medicina Biologica; 3:53-66, 2001.
    33. Bufalini L. Rieducazione nutrizionale e terapia omotossicologica in pazienti anoressiche amenorroiche. La Medicina Biologica; 3:67-71, 2001.
    34. Polito A. Encefalopatia portosistemica in fase terminale in paziente cirrotico: Terapia con SON Formula. La Medicina Biologica; 49-50, 2001.
    35. Tamburlin N. Correlazioni tra micosi cutanuee ed intolleranze alimentari. La Medicina Biologica; 67-75, 2001.
    36. De Cristofano C., Giordano F. Terapia omeopatica integrata in un caso di cirrosi epatica scompensata. La Medicina Biologica; 51-52, 2002.
    37. Lucà-Moretti, M., Grandi A., Lucà E., Mariani E., Vender G., Arrigotti E., Ferrario M., Rovelli E. Comparative Results Between Two Groups of Track and Field Athletes with or without the use of Master Amino Acids Pattern® as protein substitute. Advances in Therapy; 4:195-202, 2003.
    38. Lucà-Moretti, M., Grandi A., Lucà E., Mariani E., Vender G., Arrigotti E., Ferrario M., Rovelli E Results of taking Master Amino Acids Pattern® as a sole and total substitute of dietary proteins in an athlete during a desert crossing. Advances in Therapy; 4:203-210, 2003.
    39. Lucà-Moretti, M., Grandi A., Lucà E., Muratori G., Nofroni M.G., Mucci M.P., Gambetta P., Stimolo R., Drago P., Giudice G., Tamburlin N., Karbalay M., Valente C., Moras G. Master Amino Acids Pattern® as sole and total substitute for dietary proteins during a weight loss diet to achieve the body’s Nitrogen Balance equilibrium. Advances in Therapy; 5:270-281, 2003.
    40. Lucà-Moretti, M., Grandi A., Lucà E., Muratori G., Nofroni M.G., Mucci M.P., Gambetta P., Stimolo R., Drago P., Giudice G., Tamburlin N. Master Amino Acids Pattern® as substitute for dietary proteins during a weight loss diet to achieve the body’s Nitrogen Balance equilibrium with essentially no calories. Advances in Therapy; 5:282-291, 2003.
    41. Ripa S. Il programma SON Formula. Argomenti di medicina estetica biologica; Guna Ed., Milano, 2004.
    42. Marucci S. Linfedema ereditario e malassorbimento proteico con deficit secondario di HGH. La Medicina Biologica; 21-25, 2004.
    43. Turco L. Rete ippocampale come modello della late-life: approccio farmacologico di regolazione nel senex. La Medicina Biologica; 55-59, 2004.
    44. Penco P., Frigerio F., Orlandi S., Molinari R. Progetto SET/K13: Rilievi su un caso estremo. La Medicina Biologica; 15-22, 2006.
    45. Lanza A. Intrauterine Growth Restriction prevention by Master Amino Acid Pattern. Atti del XXI Congresso Nazionale di Omeopatia, Omotossicologia e Medicina Biologica. La Medicina Biologica; 4:35-43, 2006.
    46. Ruggiero M., Ward E., Smith R., Branca J., Noakes D., Morucci G., Taubmann M., Thyer L., Pacini S. Oleic Acid, Deglycosylated Vitamin D-Binding Protein, Nitric Oxide: A molecular Triad Made Lethal to Cancer. Anticancer Research 34; 569-3578, 2014.